Vectura joins the 'smart inhaler' party with Propeller partnership


There’s yet another respiratory drugmaker jumping on the “smart inhaler” bandwagon--and that’s the U.K.’s Vectura.

Tuesday, the Chippenham-based company announced it would be joining hands with Wisconsin’s Propeller Health in the development of an add-on sensor for Vectura’s lever-operated multi-dose inhaler. That sensor, in turn--along with Propeller’s companion analytics interface--will help patients and doctors better control respiratory disease, with patients becoming “more engaged with their care and better equipped to understand their disease and improve self-management,” Vectura said in a statement.

And the partnership may not end there; the pair is discussing “additional connected strategies” for other respiratory devices in Vectura’s pipeline, the drugmaker noted.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

With a host of companies scrambling to find--and keep--their footing in a crowded respiratory field, Vectura is hardly the first to turn to smart inhalers--or even to Propeller. Late last year, GlaxoSmithKline ($GSK) inked a pact with the Madison company to create a custom sensor for its Ellipta inhaler that would collect and record data on the date and time of each use of the device. Boehringer Ingelheim--which first joined up with Propeller back in 2013--struck an accord even more recently, agreeing in March to team on an effort to generate real-world data with Propeller’s inhaler tech.

It’s not just Propeller getting in on the Big Pharma action, either. Novartis ($NVS), which is working to wrestle respiratory share away from giant Glaxo, in January unveiled a collaboration with Qualcomm to develop the next generation of its Breezhaler inhaler, used with each of the meds in the Swiss drugmaker’s portfolio.

And then there are the pharmas who have opted to go a different route than partnership. AstraZeneca ($AZN) has already socked $3 million into smart inhaler company Adherium, mobihealthnews reports, and last September, Teva ($TEVA) bought Massachusetts’ Gecko Health Innovations outright.

- read Vectura's release
- get more from mobihealthnews

Special Report: The 10 best-selling drugs of 2013 - Advair/Seretide

Related Articles:
Looking for a respiratory edge, Boehringer teams with Propeller to test 'smart inhaler' for adherence
Novartis matches respiratory rivals with 'smart inhaler' collaboration​
GSK jumps on the 'smart inhaler' bandwagon with Ellipta sensor deal

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.